MedTrace Logo

Etanercept Survival in Elderly Population

NCT02503059 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2015-07-20

No results posted yet for this study

Summary

Evaluate the 3-year survival of etanercept in patients over 60 years with psoriasis in moderate / severe plaque and the reasons that led to the abandonment. Besides factors that might have had a positive or negative influence on adherence to treatment and analysis of efficacy (PASI 75) and safety will be identified.

All variables were collected through retrospective review of medical records of patients dermatology unit are made.

Conditions

Sponsors & Collaborators

  • Fundación Pública Andaluza Progreso y Salud

    lead OTHER

Principal Investigators

  • Enrique Herrera Ceballos, MD · H.U. Virgen de la Victoria

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2015-01-31
Completion
2015-02-28

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02503059 on ClinicalTrials.gov